P53 mutants without a functional tetramerisation domain are not oncogenic 1 1Edited by A. R. Fersht

This publication has 20 references indexed in Scilit:

• Characterization of the oligomerization defects of two p53 mutants found in families with Li–Fraumeni and Li–Fraumeni-like syndrome
  Oncogene, 1998
• In vitro analysis of the dominant negative effect of p53 mutants
  Journal of Molecular Biology, 1998
• Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain
  Molecular and Cellular Biology, 1998
• An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control
  Proceedings of the National Academy of Sciences, 1998
• In vitro structure-function analysis of the β-strand 326-333 of human p53
  Journal of Molecular Biology, 1997
• Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents
  Nucleic Acids Research, 1996
• WAF1, a potential mediator of p53 tumor suppression
  Cell, 1993
• Gain of function mutations in p53
  Nature Genetics, 1993
• Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
  Science, 1992
• p53 Mutations in Human Cancers
  Science, 1991